[Effect of a new synthetic anticholinergic (oxytropium bromide) on acetylcholine-induced bronchospasm].
Oxytropium bromide, a new synthetic anticholinergic agent, delivered by a dose inhaler, was compared to a placebo in a cross-over double-blind trial. The drop in FEV1 after administration of increasing doses of acetylcholine aerosol spray was measured 45 min after administration of the test drug, and the dose-response curve was determined. The placebo modified neither acetylcholine threshold dose (bronchial sensitivity) nor the slope of the curve (bronchial reactivity). Oxytropium bromide elevated the response threshold and decreased bronchial reactivity to vagal stimuli.
D000109:Acetylcholine / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D001986:Bronchial Spasm / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use*; D012138:Respiratory Therapy; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000627:therapeutic use*
D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C017590:oxitropium; D000109:Acetylcholine
Effet d'un nouvel anticholinergique de synthèse (oxytropium bromide) sur le bronchospasme induit par l'acétylcholine.